Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot Consistency of Covifenz COVID-19 Vaccine
NCT05040789Phase 3Withdrawn
- Sponsor
- Medicago Inc.
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Covifenz in coronavirus disease 2019 (COVID-19), sponsored by Medicago Inc.. Planned start Nov 2021; status: withdrawn.
02
Drugs
Covifenz
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05040789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040789.